Page last updated: 2024-12-06

madecassic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Madecassic acid is a triterpenoid compound found in the herb Centella asiatica, also known as Gotu kola. It has been shown to exhibit various pharmacological activities, including wound healing, anti-inflammatory, antioxidant, and neuroprotective effects. Research suggests that madecassic acid promotes collagen synthesis, stimulates angiogenesis (formation of new blood vessels), and reduces inflammation, contributing to its wound-healing properties. It is studied extensively due to its potential therapeutic applications in dermatology, particularly for the treatment of skin wounds, burns, ulcers, and acne. Madecassic acid is also being investigated for its potential benefits in treating neurological disorders, Alzheimer's disease, and cancer.'

Cross-References

ID SourceID
PubMed CID73412
CHEMBL ID481854
CHEBI ID73058
SCHEMBL ID153239
MeSH IDM0041940
PubMed CID6710742
MeSH IDM0041940

Synonyms (59)

Synonym
AC-6055
unii-m7o1n24j82
urs-12-en-28-oic acid, 2,3,6,23-tetrahydroxy-, (2alpha,3beta,4alpha,6beta)-
m7o1n24j82 ,
nsc 88135
brahmic acid
bdbm50244879
(1s,2r,4as,6as,6br,8r,8ar,9r,10r,11r,12ar,12br,14bs)-8,10,11-trihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid
(1s,2r,4as,6ar,6as,6br,8r,8ar,9r,10r,11r,12ar,14bs)-8,10,11-trihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1h-picene-4a-carboxylic acid
CHEMBL481854 ,
chebi:73058 ,
S9502
(2alpha,3beta,6beta)-2,3,6,23-tetrahydroxyurs-12-en-28-oic acid
6beta-hydroxyasiatic acid
AKOS015896782
CCG-208587
SCHEMBL153239
urs-12-en-28-oic acid, 2,3,6,23-tetrahydroxy-, (2.alpha.,3.beta.,4.alpha.,6.beta.)-
urs-12-en-28-oic acid, 2.alpha.,3.beta.,6.beta.,23-tetrahydroxy-
madecassic acid (constituent of centella asiatica) [dsc]
oristract mda
6.beta.-hydroxyasiatic acid
madecassic acid [inci]
madecassic acid [who-dd]
2.alpha.,3.beta.,6.beta.,23-tetrahydroxy-urs-12-en-28-oic acid
sr-05000002181
SR-05000002181-2
SR-05000002181-3
6-hydroxyasiatic acid
(1s,2r,4as,6ar,6as,6br,8r,8ar,9r,10r,11r,12ar,14bs)-8,10,11-trihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1h-picene-4a-carboxylicacid
HY-N0569
DB14037
DTXSID70939838
urs-12-en-28-oic acid, 2,3,6,23-tetrahydroxy-, (2a,3b,4a,6b)-
CS-0009106
2alpha,3beta,6beta,23-tetrahydroxyurs-12-en-28-oic acid
madecassic acid (constituent of centella asiatica)
2alpha,3beta,6beta,23-tetrahydroxy-urs-12-en-28-oic acid
callicos cellawake mask madecassol
urs-12-en-28-oic acid, 2alpha,3beta,6beta,23-tetrahydroxy-
BRD-A84189249-001-02-4
SDCCGMLS-0066788.P001
SPECTRUM4_001976
2,3,6,23-tetrahydroxyurs-12-en-28-oic acid
NCGC00178570-01
BSPBIO_002621
SPECTRUM5_000847
madecassic acid ,
KBIOGR_002477
KBIO3_002121
SPECTRUM2_000488
SPECTRUM3_001131
SPBIO_000355
SPECTRUM1505250
CCG-38710
(4r)-2alpha,3beta,6beta,23-tetrahydroxyurs-12-en-28-oic acid
LMPR0106180009
6b-hydroxyasiatic acid
BRD-A84189249-001-03-2

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The developed method was successfully applied to the pharmacokinetic study of madecassoside and madecassic acid in rats after an oral administration of madecassoside."( A LC-ESI-MS method for the simultaneous determination of madecassoside and its metabolite madecassic acid in rat plasma: comparison pharmacokinetics in normal and collagen-induced arthritic rats.
Dai, Y; Gao, FF; Jiang, CJ; Leng, DD; Wang, T; Xia, YF, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of 29 was significantly improved in comparison with its aglycon."( Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid.
Chen, C; Cheng, K; Dai, L; Hu, K; Li, H; Liu, L; Sun, H; Wen, X; Xu, Q; Yuan, H, 2021
)
0.62
" However, the efficacy of MCA is limited by low oral bioavailability caused by its extremely poor aqueous solubility."( Self-Nanoemulsifying Drug Delivery System for Enhanced Bioavailability of Madecassic Acid: In vitro and in vivo Evaluation.
Chen, Q; Dai, Y; Lin, L; Xia, Y, 2023
)
0.91
"This study reports the MCA-loaded SNEDDS with distinctly enhanced in vitro and in vivo performance compared with pure MCA and concludes that the SNEDDS formulation could be a viable and effective strategy for improving the dissolution rate and bioavailability of poor aqueous-soluble ingredients."( Self-Nanoemulsifying Drug Delivery System for Enhanced Bioavailability of Madecassic Acid: In vitro and in vivo Evaluation.
Chen, Q; Dai, Y; Lin, L; Xia, Y, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pentacyclic triterpenoid
tetrolA polyol that contains 4 hydroxy groups.
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)IC50 (µMol)20.00000.70004.58049.4500AID409687
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)12.38000.00053.49849.7600AID409686
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (67)

Processvia Protein(s)Taxonomy
microtubule cytoskeleton organizationRhodopsinBos taurus (cattle)
visual perceptionRhodopsinBos taurus (cattle)
phototransduction, visible lightRhodopsinBos taurus (cattle)
response to light stimulusRhodopsinBos taurus (cattle)
response to light intensityRhodopsinBos taurus (cattle)
gene expressionRhodopsinBos taurus (cattle)
absorption of visible lightRhodopsinBos taurus (cattle)
rhodopsin mediated signaling pathwayRhodopsinBos taurus (cattle)
thermotaxisRhodopsinBos taurus (cattle)
photoreceptor cell maintenanceRhodopsinBos taurus (cattle)
detection of temperature stimulus involved in thermoceptionRhodopsinBos taurus (cattle)
podosome assemblyRhodopsinBos taurus (cattle)
rod bipolar cell differentiationRhodopsinBos taurus (cattle)
negative regulation of transcription by RNA polymerase IITyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of lipid storageTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
B cell differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
T cell differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
erythrocyte differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
glucose homeostasisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of macrophage differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of gluconeogenesisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of inflammatory responseTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of chemotaxisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
regulation of type II interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-6-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-2-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-4-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of macrophage colony-stimulating factor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of positive thymic T cell selectionTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingRhodopsinBos taurus (cattle)
opsin bindingRhodopsinBos taurus (cattle)
guanyl-nucleotide exchange factor activityRhodopsinBos taurus (cattle)
11-cis retinal bindingRhodopsinBos taurus (cattle)
protein bindingRhodopsinBos taurus (cattle)
G protein-coupled photoreceptor activityRhodopsinBos taurus (cattle)
zinc ion bindingRhodopsinBos taurus (cattle)
identical protein bindingRhodopsinBos taurus (cattle)
arrestin family protein bindingRhodopsinBos taurus (cattle)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
integrin bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
syntaxin bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
STAT family protein bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
Golgi membraneRhodopsinBos taurus (cattle)
photoreceptor disc membraneRhodopsinBos taurus (cattle)
plasma membraneRhodopsinBos taurus (cattle)
cell-cell junctionRhodopsinBos taurus (cattle)
membraneRhodopsinBos taurus (cattle)
outer membraneRhodopsinBos taurus (cattle)
photoreceptor outer segment membraneRhodopsinBos taurus (cattle)
photoreceptor inner segment membraneRhodopsinBos taurus (cattle)
sperm midpieceRhodopsinBos taurus (cattle)
rod photoreceptor outer segmentRhodopsinBos taurus (cattle)
sperm head plasma membraneRhodopsinBos taurus (cattle)
G protein-coupled receptor complexRhodopsinBos taurus (cattle)
plasma membraneTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (135)

Assay IDTitleYearJournalArticle
AID1539328Antiproliferative activity against human UO31 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539303Antiproliferative activity against human SNB75 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539262Antiproliferative activity against human A498 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539254Antiproliferative activity against human IGROV1 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539290Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539286Antiproliferative activity against human HOP92 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539227Antiproliferative activity against human NCI-H226 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539253Antiproliferative activity against human UACC62 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539292Antiproliferative activity against human COLO205 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539239Antiproliferative activity against human SF268 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539293Antiproliferative activity against human HCC2998 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539331Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539237Antiproliferative activity against human KM12 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID409686Inhibition of PTP1B by pNPP assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Oleanolic acid and its derivatives: new inhibitor of protein tyrosine phosphatase 1B with cellular activities.
AID1539235Antiproliferative activity against human HCT15 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539295Antiproliferative activity against human HCT15 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539307Antiproliferative activity against human M14 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539224Antiproliferative activity against human EKVX cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539330Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID409687Inhibition of TCPTP by pNPP assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Oleanolic acid and its derivatives: new inhibitor of protein tyrosine phosphatase 1B with cellular activities.
AID1539259Antiproliferative activity against human NCI/ADR-RES cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539288Antiproliferative activity against human NCI-H23 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539324Antiproliferative activity against human Caki1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539285Antiproliferative activity against human HOP62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539287Antiproliferative activity against human NCI-H226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539316Antiproliferative activity against human OVCAR4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539297Antiproliferative activity against human KM12 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539294Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539225Antiproliferative activity against human HOP62 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539247Antiproliferative activity against human M14 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539276Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539289Antiproliferative activity against human NCI-H322M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539217Antiproliferative activity against human CCRF-CEM cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539255Antiproliferative activity against human OVCAR3 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539238Antiproliferative activity against human SW620 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1728066Activation of AMPK in human Huh-7 cells assessed as increase in AMPK phosphorylation at Thr172 residue at 10 uM measured after 12 hrs by Western blot analysis2021European journal of medicinal chemistry, Jan-01, Volume: 209Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid.
AID1539320Antiproliferative activity against human SKOV3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539301Antiproliferative activity against human SF539 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539335Antiproliferative activity against human T47D cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539244Antiproliferative activity against human U251 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539305Antiproliferative activity against human LOXIMVI cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539274Antiproliferative activity against human BT549 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539269Antiproliferative activity against human PC3 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539304Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539248Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1666863Inhibition of swarming motility of Pseudomonas aeruginosa HONKR at 16 ug/mL incubated for 16 to 20 hrs relative to control2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Optimized plant compound with potent anti-biofilm activity across gram-negative species.
AID1539220Antiproliferative activity against human MOLT4 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539240Antiproliferative activity against human SF295 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539260Antiproliferative activity against human SKOV3 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID38498In vitro percent protective effect against Amyloid Beta(A beta)-induced neurotoxicity in B103 cells2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Structure-activity relationship study of asiatic acid derivatives against beta amyloid (A beta)-induced neurotoxicity.
AID1539306Antiproliferative activity against human MALME-3M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539318Antiproliferative activity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539267Antiproliferative activity against human TK10 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539282Antiproliferative activity against human SR cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539284Antiproliferative activity against human EKVX cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539245Antiproliferative activity against human LOXIMVI cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539266Antiproliferative activity against human SN12C cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID365154Binding affinity to photoactivated rhodopsin in bovine retinal rod outer-segment membranes assessed as induction of extra receptor MII state stabilization by UV/visible difference spectroscopy2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening.
AID1539334Antiproliferative activity against human BT549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539252Antiproliferative activity against human UACC257 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539272Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539219Antiproliferative activity against human K562 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539251Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539222Antiproliferative activity against human SR cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539263Antiproliferative activity against human ACHN cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539321Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539223Antiproliferative activity against human A549/ATCC cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1539336Antiproliferative activity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID366251Inhibition of Spirulina platensis adenylyl cyclase assessed as cAMP level by cAMP immunogenic assay2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Structure-based development of novel adenylyl cyclase inhibitors.
AID1539280Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539310Antiproliferative activity against human SK-MEL-28 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539309Antiproliferative activity against human SK-MEL-2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539275Antiproliferative activity against human T47D cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539243Antiproliferative activity against human SNB75 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539300Antiproliferative activity against human SF295 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539299Antiproliferative activity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539329Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539228Antiproliferative activity against human NCI-H23 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539317Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539221Antiproliferative activity against human RPMI8226 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539250Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1539332Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539261Antiproliferative activity against human 786-0 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539249Antiproliferative activity against human SK-MEL-2 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539256Antiproliferative activity against human OVCAR4 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539279Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539327Antiproliferative activity against human TK10 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539323Antiproliferative activity against human ACHN cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539333Antiproliferative activity against human Hs 578T cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539236Antiproliferative activity against human HT-29 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539315Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539268Antiproliferative activity against human UO31 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539302Antiproliferative activity against human SNB19 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539233Antiproliferative activity against human HCC2998 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539298Antiproliferative activity against human SW620 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539319Antiproliferative activity against human NCI/ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539218Antiproliferative activity against human HL-60(TB) cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539271Antiproliferative activity against human MCF7 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539326Antiproliferative activity against human SN12C cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539314Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539234Antiproliferative activity against human HCT116 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1158457Enhancement of GLUT4 translocation in rat L6 cells expressing pIRAP-mOrange cDNAs at 10 uM after 10 mins by fluorescence assay relative to control2014Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14
Chemical constituents from Eucalyptus citriodora Hook leaves and their glucose transporter 4 translocation activities.
AID1539242Antiproliferative activity against human SNB19 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539313Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539311Antiproliferative activity against human SK-MEL-5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539265Antiproliferative activity against human RXF393 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1539230Antiproliferative activity against human NCI-H460 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539325Antiproliferative activity against human RXF393 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1539296Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539258Antiproliferative activity against human OVCAR8 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539277Antiproliferative activity against human CCRF-CEM cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539231Antiproliferative activity against human NCI-H522 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID404873Inhibition of rabbit muscle glycogen phosphorylase A assessed as phosphate release from glucose-1-phosphate2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystallographic studies.
AID1539308Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539232Antiproliferative activity against human COLO205 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539270Antiproliferative activity against human DU145 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539257Antiproliferative activity against human OVCAR5 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539241Antiproliferative activity against human SF539 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539283Antiproliferative activity against human A549/ATCC cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539226Antiproliferative activity against human HOP92 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID365155Inhibition of bovine retinal rod outer-segment photoactivated rhodopsin-transducer interaction by transducer release assay2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening.
AID1539229Antiproliferative activity against human NCI-H322M cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539273Antiproliferative activity against human Hs 578T cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539312Antiproliferative activity against human UACC257 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539281Antiproliferative activity against human RPMI8226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539246Antiproliferative activity against human MALME-3M cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539278Antiproliferative activity against human HL-60(TB) cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539264Antiproliferative activity against human Caki1 cells assessed as cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539322Antiproliferative activity against human A498 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1539291Antiproliferative activity against human NCI-H522 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (8.89)18.2507
2000's10 (22.22)29.6817
2010's22 (48.89)24.3611
2020's9 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.90 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index70.95 (26.88)
Search Engine Supply Index2.07 (0.95)

This Compound (47.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Reviews2 (5.71%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1 (2.86%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
Other32 (91.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]